Heron Therapeutics

Traded on the St. Petersburg Stock Exchange
Heron Therapeutics, Inc. operates as a biotechnology company. The Company offers proprietary biochronomer drug delivery technology.
Heron Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Heron Therapeutics balance sheet

Report period2018 2019 2020 2021 2022Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Heron Therapeutics cash flows

Report period2018 2019 2020 2021 2022Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Heron Therapeutics multipliers

Report period2018 2019 2020 2021 2022Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Heron Therapeutics profitability

Report period2018 2019 2020 2021 2022Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Heron Therapeutics assets
Heron Therapeutics cash flows

Heron Therapeutics shares

TickerNameTypeNominal valueISINPrice
HRTX:USHeron Therapeutics, Inc.Common share-US4277461020$1.77
Heron Therapeutics news
10.05.2022
Heron Therapeutics reported a GAAP loss of $63.888 million for the first 3 months of 2022, up 21.4% from $52.614 million in the prior year. Revenue increased 17.2% to $23.457 million from $20.018 million a year earlier.
Source: {source} pictogram ir.herontx.com
Pictogram next
17.03.2022
Heron Therapeutics has received approval from Health Canada for Zynrelef. The drug is intended for pain management in adults after surgeries such as bunionectomy, open inguinal gerniorrhaphy, or total knee arthroplasty.
Source: {source} pictogram ir.herontx.com
Pictogram next
01.03.2022
Heron Therapeutics' GAAP loss for 2021 was $220.683 million, down 2.9% from $227.278 million in the prior year. Revenue declined 2.6% to $86.346 million from $88.638 million a year earlier.
Source: {source} pictogram ir.herontx.com
Pictogram next
04.11.2021
Heron Therapeutics reported a GAAP loss of $166.037 million for 9M 2021, up 0.6% from $164.997 million in the previous year. Revenues decreased by 3.4% to $65.691 million from $68.033 million a year earlier.
Source: {source} pictogram ir.herontx.com
Pictogram next
All Heron Therapeutics news
General information
Company nameHeron Therapeutics
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address4242 CAMPUS POINT COURT, SUITE 200 SAN DIEGO CA 92121 8582514400
Mailing address4242 CAMPUS POINT COURT, SUITE 200 SAN DIEGO CA 92121
Websitewww.herontx.com
Information disclosurewww.sec.gov